A.O. Smith Boosts FY21 Outlook - Quick Facts

While reporting financial results for the second quarter on Thursday, A.O. Smith Corp. (AOS) raised its adjusted earnings and sales growth guidance for the full-year 2021, based on solid demand for its products.

For fiscal 2021, the company now projects adjusted earnings in a range of $2.70 to $2.76 per share on sales growth between 17 and 18 percent.

Previously, the company expected adjusted earnings in a range of $2.55 to $2.65 per share on sales growth between 14 and 15 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.70 per share on sales growth of 15.4 percent to $3.34 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT